Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Amy B. Heimberger|Neuro-Oncology|2019Cited by 165
Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in GlioblastomaJohn de Groot, Amy B. Heimberger|Oncotarget|2012Cited by 84
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse modelsYuji Piao, John de Groot|Neuro-Oncology|2016Cited by 67
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent <i>IDH</i> wild-type glioblastomaJohn de Groot, Eric C. Leuthardt, Costas G. Hadjipanayis et al.|Neuro-Oncology Advances|2022Cited by 61
Long‐term survival among 5‐year survivors of adolescent and young adult cancerAmy M. Berkman, Michael Roth, J. Andrew Livingston et al.|Cancer|2020Cited by 56